ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

NCAB Hears “Impressive” Progress Reports, Including Treatment for Breast, Liver Cancer, Vaccine Studies

October 18, 1974

News Analysis: The Political Economy of Importation to Alleviate Cancer Drug Shortages

March 2, 2012

Young Investigator Grants Available

July 8, 1977

NCI Cooperative Group Clinical Trials Approved

September 25, 2009

Interview: “People don’t understand Clinical Trials.

September 5, 1997

Correcting the Error: What U.S. News Could and Couldn’t Do to Fix the Problem

July 19, 2013